Skip to main content
. 2023 Oct 20;7(22):7067–7078. doi: 10.1182/bloodadvances.2023010658

Table 3.

Somatic mutations in the AML cohort

High-TERRA AML, n (%) Low-TERRA AML, n (%) Fisher test (P value)
Patients sequenced 37 42
Splicing factors 3 (8) 12 (28) P < .05
Epigenetic modifiers 13 (35) 12 (28) n.s.
RUNX1 1 (3) 6 (14) n.s.
ASXL1 0 (−) 2 (5) n.s.
TP53 0 (−) 3 (7) n.s.

n.s., nonsignificant. Boldface indicates not all patients included in the initial cohort were sequenced.